The Pluralistic Landscape
American medicine before 1910 was a competitive marketplace of therapeutic traditions with no single orthodoxy holding unchallenged authority. The dominant school numerically was what is now called allopathy — the tradition descended from European humoral medicine that had progressively adopted the germ theory, pharmacological intervention, and surgical practice as its operational methods. Allopathy was the largest of the American medical traditions by the late nineteenth century, but it was one tradition among several, and its position was contested on multiple fronts by competing schools that had their own medical schools, their own licensing arrangements in states where such arrangements existed, their own patient populations, and their own theoretical frameworks.
Homeopathy, founded by Samuel Hahnemann in Germany in the 1790s and brought to the United States in the 1820s, operated on the principle that substances producing symptoms resembling a disease in a healthy person could cure that disease in a sick person when administered at extremely low dilutions. The theoretical basis was speculative by the standards of modern pharmacology, but the clinical results were competitive with allopathy in the specific sense that homeopathic hospitals had statistically better survival rates than allopathic hospitals during the nineteenth-century epidemics of cholera, yellow fever, and similar diseases. This was not because homeopathy’s theoretical framework was correct but because homeopathy’s characteristic practice of doing very little — administering tiny doses of water-based preparations while providing nursing care, fluids, and observation — caused less iatrogenic harm than the bleeding, purging, and toxic-mineral administration that characterized nineteenth-century allopathy. The competitive pressure homeopathy exerted on allopathy forced the allopathic tradition to abandon some of its most harmful practices during the late nineteenth century, and the two traditions coexisted in a state of mutual critique and gradual convergence.
Eclectic medicine, an American tradition founded in the 1820s, drew on botanical pharmacology from both European herbalism and Native American medicine. The Eclectic Medical Institute of Cincinnati, founded in 1845, became the tradition’s intellectual center and operated a medical school whose curriculum emphasized plant-based therapeutics, clinical observation, and a conservative approach to pharmacological intervention. The tradition produced several significant pharmacological discoveries and published a substantial scientific literature before being systematically excluded from the institutional medical framework after 1910.
Osteopathy, founded by Andrew Taylor Still in 1874, developed a theoretical framework centered on the relationship between musculoskeletal structure and systemic health, and developed a distinctive set of manual manipulation techniques for addressing this relationship. Chiropractic, founded by Daniel David Palmer in 1895, developed a related but distinct framework emphasizing spinal alignment. Both traditions established medical schools, clinical practices, and professional associations. Naturopathy developed as a synthesis of European nature-cure practices, hydrotherapy, nutritional therapeutics, and herbalism, producing its own professional infrastructure by the early twentieth century.
Other traditions operated at smaller scale: Thomsonian herbalism, Christian Science, physiomedicalism, hydropathy, the Kellogg brothers’ sanitarium movement, and various regional and ethnic medical traditions serving specific populations. The cumulative effect was a medical landscape in which no single tradition possessed the authority to exclude the others, in which patients could choose among competing approaches on the basis of their own experience and preference, and in which the various traditions competed through results rather than through institutional monopoly. This was the situation the Flexner Report was commissioned to address, and address it did — by eliminating the competition.
The Flexner Report
Abraham Flexner was an educational reformer who had operated a private preparatory school in Louisville, Kentucky — he held no medical training and no academic medical credentials. The Carnegie Foundation for the Advancement of Teaching commissioned him in 1908 to survey the state of American medical education and produce recommendations for its reform. The commission originated with the AMA’s Council on Medical Education, which had been pursuing consolidation since its founding in 1904 and contracted Carnegie to provide external credibility to a reform agenda the AMA had already determined to pursue. That Flexner’s brother Simon served as director of laboratories at the Rockefeller Institute for Medical Research — the centerpiece of the pharmaceutical-research model Abraham’s report would recommend — is a structural fact the report’s defenders have not satisfactorily addressed. Flexner spent the following eighteen months visiting all 155 medical schools then operating in the United States and Canada, evaluating their facilities, curricula, faculty qualifications, entrance requirements, and laboratory equipment against the standard he regarded as the target for legitimate medical education: the Johns Hopkins University School of Medicine, which had opened in 1893 and had been modeled explicitly on the German research university tradition.
Medical Education in the United States and Canada, published as Carnegie Foundation Bulletin Number Four in June 1910, presented Flexner’s findings. The document — universally known as the Flexner Report — is approximately three hundred fifty pages long and provides a school-by-school assessment of every medical institution Flexner had visited. The conclusion was that the majority of American medical schools were inadequate by the Johns Hopkins standard: their facilities were insufficient, their entrance requirements too low, their curricula unscientific, their laboratory capabilities absent or primitive, and their graduates unprepared for the practice of scientific medicine. Flexner recommended that approximately two-thirds of the existing schools should be closed outright and that the remaining schools should be restructured on the Johns Hopkins model — with full-time scientifically trained faculty, extensive laboratory facilities, four-year curricula, hospital affiliations, and entrance requirements that included at least two years of undergraduate education in the natural sciences.
The report’s specific methodological choice — evaluating all medical schools against a standard drawn from one particular medical tradition — built the outcome into the evaluation. Homeopathic schools were assessed against a curriculum that treated homeopathy as inadequate a priori. Eclectic schools were assessed against a laboratory standard that made their botanical pharmacology appear unscientific by comparison with the pharmacological chemistry that the allopathic tradition had adopted. Osteopathic schools were assessed by criteria that had no category for the manipulative therapeutics the tradition regarded as central to its practice. The assessment was rigorous within the framework it applied, and the framework excluded every tradition except the one being used as the measuring rod. The schools that failed the evaluation failed because the evaluation had been designed in a way that they could not pass.
The report was not, on its face, a document targeting any particular tradition for elimination. Flexner’s stated concern was genuine quality — the many diploma mills and for-profit schools that had indeed produced incompetent graduates and that had earned much of the criticism Flexner directed at them. The problem with the report is not that its criticism was wrong but that its criticism applied uniformly to traditions with fundamentally different epistemological foundations, and that the reform it recommended entailed the elimination of traditions whose quality issues were largely independent of the pedagogical problems Flexner was identifying. A homeopathic medical school could meet every one of Flexner’s pedagogical standards while remaining homeopathic — full-time faculty, laboratory facilities, four-year curriculum, entrance requirements, hospital affiliation — and still be excluded from the reformed landscape because homeopathy itself was the problem Flexner’s framework treated as the deeper issue. The reform, in other words, conflated institutional pedagogy with therapeutic tradition and used the former to eliminate the latter.
The consolidation the report drove excluded not only therapeutic traditions but also racial and gender diversity in the profession. The same funding-gatekeeping mechanism that closed homeopathic schools also closed Black medical colleges: of seven historically Black medical schools operating before the reform, five were closed, leaving only Howard University and Meharry Medical College. Women’s medical education contracted under similar pressure. The Association of American Medical Colleges renamed its Flexner Award in 2020 specifically in acknowledgment of this history — a tacit institutional concession that the report’s structural consequences extended well beyond the pedagogical deficiencies it had identified.
The Funding Architecture
What made the Flexner Report consequential rather than merely influential was the funding architecture that implemented its recommendations. The Carnegie Foundation had commissioned the report. The General Education Board — established in 1902 as a distinct Rockefeller philanthropic instrument, chartered by Congress specifically for educational reform — provided the capital to reshape American medical education along the lines Flexner had recommended. The Rockefeller Foundation, chartered in 1913 as a separate and additional organization, extended the work across broader domains; both institutions operated in close coordination throughout this period, with prominent figures holding positions in both. The intellectual architect behind the strategy was Frederick T. Gates, Rockefeller Sr.’s principal philanthropic adviser, who had read William Osler’s The Principles and Practice of Medicine and written a memorandum to Rockefeller recommending the establishment of a scientific medical research institute — a vision directly realized in the Rockefeller Institute for Medical Research, founded in 1901. Between 1910 and 1930, the General Education Board directed approximately sixty-five million dollars specifically to medical schools — substantial enough to determine institutional survival — while total Rockefeller philanthropic giving to higher education in the same period reached several hundred million dollars. Funding was conditional on receiving schools meeting the Flexner standards. Schools that agreed received the capital required to build laboratories, hire full-time faculty, and restructure their curricula. Schools that did not agree received nothing and were gradually unable to compete with the reformed institutions.
The selection of which schools received funding was not neutral. The Rockefeller money flowed to allopathic institutions that were committed to the scientific-pharmacological model Flexner had endorsed. Homeopathic, eclectic, and other competing-tradition schools were excluded from the funding stream as a matter of policy. Within a generation, the schools that had not received Rockefeller support either closed, abandoned their distinctive traditions in order to qualify for support, or reduced to marginal operations serving shrinking patient populations. By 1930 the American medical landscape had been transformed: the number of medical schools had dropped from 155 to approximately 76 (by 1935, fewer than 66 remained), the competing traditions had been largely eliminated from mainstream medical education, the surviving schools were uniform in curriculum and approach, and the graduating physicians were products of a homogeneous training system that taught the scientific-pharmacological model as the only legitimate medicine.
The Rockefeller philanthropies were not engaged in this work out of abstract interest in medical quality. John D. Rockefeller Sr. had built the Standard Oil Trust into the largest and wealthiest corporation in American history, and the Rockefeller industrial interests included substantial investments in the petrochemical industry whose refining operations produced the raw materials from which synthetic pharmaceuticals were manufactured. The pharmaceutical industry in 1910 was a small and fragmented sector of the American economy. By 1950 it was one of the largest and most profitable sectors, and the transition had been accomplished in part by the medical education reform that produced a profession whose members were trained to prescribe synthetic pharmaceuticals as the primary mode of therapeutic intervention. The Rockefeller Foundation had not created this outcome directly through corporate strategy. It had created it indirectly by funding the restructuring of medical education in ways that made synthetic pharmacology the default therapeutic tool and the botanical, homeopathic, and other traditions the marginalized alternatives. The outcome was congruent with the interests of the petrochemical industry the Rockefeller wealth had been built on, and the congruence is the structural point the critical literature on the Flexner Report has been making for half a century.
E. Richard Brown’s Rockefeller Medicine Men: Medicine and Capitalism in America (1979) provided the first comprehensive scholarly documentation of this pattern. Brown’s work — based on the Rockefeller Foundation’s own archives, made accessible to researchers in the 1970s — established that the funding strategy was not incidental but was pursued with awareness of its commercial implications, and that the philanthropic framing of the work served to obscure the economic logic that was operating alongside the public health logic. The two logics were not incompatible. A medical reform that produced better-trained doctors could also produce a more profitable pharmaceutical industry, and the reform that Flexner had recommended and Rockefeller had funded accomplished both. The problem is not that the reform was purely economic. The problem is that the public-health framing has historically been used to preempt critical analysis of the economic dimension, and the pharmaceutical industry that emerged from the reform has inherited the same framing as its default defense against subsequent criticism.
The American Medical Association
The American Medical Association — founded in 1847, but weak and fragmentary for its first fifty years — became the political instrument that consolidated the Flexner-reformed landscape and enforced its exclusions. Under the leadership of Morris Fishbein, AMA Secretary and Editor of JAMA from 1924 to 1949, the organization developed the institutional capacity to control medical licensing through state medical boards, to regulate the advertising of pharmaceutical products through its Journal of the American Medical Association, and to exclude from the profession practitioners who operated outside the approved framework. Fishbein’s tenure saw the prosecution of several high-profile cases against alternative practitioners, the most famous being the campaign against Harry Hoxsey’s herbal cancer treatment center — documented in Coulter’s Divided Legacy and in Hoxsey’s own You Don’t Have to Die (1956) — which extended over several decades and ultimately succeeded in driving Hoxsey’s operation out of the United States.
The AMA’s authority during this period derived from several sources. Its control over the state medical licensing boards meant that practitioners who were not AMA-aligned risked losing their licenses for practicing their tradition. Its editorial control over JAMA meant that pharmaceutical advertising revenues provided the association with financial resources that no competing professional organization could match. Its control over the approved list of medical schools — which it had taken over from the Flexner reform infrastructure — meant that graduates of non-approved schools could not obtain the credentials required for hospital privileges, insurance reimbursement, or state licensing. The AMA’s effective monopoly on the definition of legitimate medical practice was consolidated during the 1930s and 1940s and has been only partially loosened since.
The specific exclusions that the AMA enforced were consequential for the pharmakon tradition in ways that subsequent generations have generally failed to recognize. Botanical medicine, which had been a legitimate field of pharmacological research until the 1910s, was driven to the margins of the profession. Nutritional medicine, which had been producing clinical results through dietary intervention since the nineteenth century, was systematically excluded from the mainstream. The connection between physical health and psychological-spiritual wellbeing, which the pre-Flexner traditions had regarded as basic to medical practice, was treated as outside the legitimate scope of medicine. And the possibility that substances with consciousness-altering effects might have therapeutic applications — a possibility the pre-Flexner traditions had taken for granted — became inadmissible within the framework the AMA had consolidated. The prohibition of LSD, psilocybin, and related substances in 1970 was the culmination of a framework that had been built over the preceding sixty years to exclude any therapeutic approach the orthodoxy could not reduce to the administration of isolated synthetic molecules for specific diagnosable conditions.
The Pharmaceutical Industry
The industry that grew up within the framework the Flexner-AMA-Rockefeller architecture had established developed along lines that the framework’s logic made inevitable. The synthetic molecule is patentable; the plant is not. The patented molecule generates profit through exclusive licensing; the plant generates profit only through the marginal value of processing. The doctor-administered prescription creates a pharmacological intervention that requires paid professional mediation; the self-administered botanical does not. The standardized dose permits industrial-scale manufacturing; the plant’s variability does not. Every structural incentive in the framework the Flexner Report had recommended pushed the resulting industry toward isolated synthetic molecules administered by prescription for specific indications, and the industry followed the incentives with the predictability that basic economic analysis would anticipate.
The structural arc connecting Rockefeller industrial capital to the pharmaceutical complex that dominated the twentieth century runs through one specific corporate relationship that the standard history of medicine consistently omits. Standard Oil of New Jersey — Rockefeller’s primary corporate vehicle by the 1920s — signed cartel agreements with IG Farben, the German chemical and pharmaceutical conglomerate, in 1926 and again in the Jasco Agreement of 1929. The agreements divided global markets for synthetic chemicals, pharmaceuticals, and oil: Standard Oil received IG Farben patents for synthetic rubber; IG Farben received hydrogenation technology. Joseph Borkin’s The Crime and Punishment of IG Farben (1978) documented this relationship in detail, including the postwar reluctance to fully dissolve IG Farben — reluctance driven in part by its entanglement with American corporate interests. The postwar dissolution of IG Farben produced the companies that constitute the core of the modern European pharmaceutical industry: Bayer, BASF, and Hoechst. The structural chain is therefore: Rockefeller oil capital → medical education reform establishing synthetic-pharmacological orthodoxy → cartel agreements with the German chemical complex → the IG Farben successor companies as modern Big Pharma’s ancestral institutions. The chain is not metaphorical. The corporate genealogy is documented.
The twentieth century’s pharmaceutical achievements are real and should not be dismissed by the critical account. Antibiotics, insulin, chemotherapy, surgical anesthesia, vaccines (as a class, notwithstanding the legitimate concerns about specific products), blood pressure medications, antiretroviral therapy for HIV, and dozens of other interventions have produced genuine extensions of human life and reductions in human suffering that the pre-Flexner medical landscape had not achieved and probably could not have achieved. The structural critique of pharmaceutical orthodoxy is not the romantic claim that traditional medicine was superior and should be restored. The structural critique is that the orthodoxy excluded dimensions of medical practice the traditional landscape had understood as essential, that the exclusions have consequences, and that the consequences have become progressively more visible as the orthodoxy’s framework has been extended to domains where its limitations are most clearly exposed.
The most visible contemporary evidence of the framework’s limitations is the opioid crisis. The Sackler family, owners of Purdue Pharma, produced OxyContin and marketed it aggressively during the late 1990s and 2000s through a campaign that systematically misrepresented the drug’s addictive potential to physicians and patients. The marketing was conducted through the mechanisms the Flexner framework had installed: paid continuing medical education, journal advertising, sales representative visits to physicians, and the integration of pharmaceutical representatives into the medical decision-making environment in ways the pre-Flexner framework would have regarded as corruption. The framework had been built on the assumption that the pharmaceutical industry would operate in alignment with medical judgment to produce better patient outcomes. The Sackler case demonstrates what happens when the assumption fails: the same framework that permits the distribution of genuine pharmaceutical benefits also permits the distribution of addictive substances to populations the framework cannot protect from the industry’s own incentives. The hundreds of thousands of American deaths from opioid overdose since the mid-1990s are the framework’s failure metric, and the framework has not so far been reformed in ways that would prevent similar failures in the future.
Vaccines as the Contemporary Flashpoint
The vaccine question is the most politically charged contemporary manifestation of the Flexner framework, and it cannot be addressed responsibly without distinguishing several claims that are often conflated in popular discussion. Vaccines as a class have been shown through extensive evidence to prevent specific infectious diseases and to have saved large numbers of lives. Specific vaccine products vary widely in their risk-benefit profile and should be evaluated individually rather than defended or attacked as a class. The governmental mandate of specific vaccines raises questions about informed consent that the orthodox framework has been historically unwilling to engage. The pharmaceutical industry’s financial interest in expanded vaccine schedules has been documented well enough to warrant ongoing critical scrutiny of specific products even in the absence of blanket criticism of the category.
The structural point relevant to the pharmakon tradition is that mandatory vaccination — whatever one’s view of any specific product — represents the inverse of the traditional pharmakon relationship. The traditional pharmakon was consumed voluntarily by a prepared initiate in a ceremonial context under the guidance of a trained practitioner, with the understanding that the substance’s effects depended on the set and setting of the administration. The mandatory vaccine is administered to an unprepared population under legal compulsion without regard to individual preparation, ceremonial context, or informed consent in the strong sense the traditional framework required. The two administrations may be pharmacologically effective in different ways — the traditional administration aimed at consciousness reconfiguration, the modern vaccine at immune memory — but the structural relationship between the recipient and the substance is inverted. The traditional framework treated the recipient’s preparation as partly constitutive of the substance’s effect. The modern framework treats the recipient as a standardized biological substrate on which the substance operates without reference to the recipient’s psychological, spiritual, or contextual condition.
This structural point does not constitute a public health argument against vaccines. It constitutes a structural observation about the inversion of the pharmakon relationship that the modern pharmaceutical framework has institutionalized. The observation is compatible with a range of views on specific vaccine products and mandate policies. What the observation precludes is the framing that treats the traditional relationship as simply obsolete and the modern relationship as straightforwardly superior. The traditional framework knew things the modern framework has excluded from legitimate consideration, and the exclusion has costs the modern framework has been unwilling to measure.
Psychiatric Chemistry
The psychiatric pharmaceutical industry that developed from the 1950s forward represents the Flexner framework applied to the management of psychological and emotional conditions. The development of chlorpromazine in 1952 as the first effective antipsychotic, the MAOI and tricyclic antidepressants of the 1950s and 1960s, the benzodiazepine anxiolytics introduced in the 1960s, and the selective serotonin reuptake inhibitors that dominated psychiatric prescribing from the late 1980s forward produced a progressive transformation in how psychiatric conditions were understood and treated. The transformation moved the field from a psychoanalytic framework emphasizing conflict resolution through interpretive therapy toward a biomedical framework emphasizing chemical imbalance correction through prescribed pharmaceuticals.
The framework’s limitations became visible during the subsequent decades, most acutely in the schizophrenia literature where twenty-year longitudinal data showed unmedicated patients outperforming continuously medicated ones at every follow-up. Robert Whitaker’s Anatomy of an Epidemic (2010) documented that the introduction and expansion of psychiatric pharmacology correlated with an increase rather than a decrease in the prevalence of chronic psychiatric disability in the United States. The finding is difficult to reconcile with the framework’s own stated assumptions: if the medications corrected chemical imbalances, then the medications should have reduced the population of people experiencing the conditions the imbalances caused. The observed pattern was the opposite. The more psychiatric pharmaceuticals were prescribed, the larger the population of people diagnosed with the conditions those pharmaceuticals were supposed to treat. The finding can be interpreted in several ways — expanded diagnostic criteria, increased help-seeking behavior, previously underdiagnosed populations becoming visible — but the interpretations most compatible with the pharmacological framework do not account for the long-term increase in chronic disability that the framework had predicted should decline.
The rendering-model reading of psychiatric pharmacology is that the conditions the medications were treating were not primarily chemical imbalances in the sense the framework assumed. They were, in most cases, appropriate responses by the instrument to conditions the consensus rendering was unable to adequately address — grief without ritual, meaning loss without cultural framework, existential confrontation without initiatic support, the accumulated trauma of life in conditions the instrument was not designed to metabolize. The chemical management of these responses did not solve the underlying conditions; it masked them, leaving the person functional within the consensus framework at the cost of the experiential signals that would have motivated them to seek a different kind of attention to what was actually happening. The traditional frameworks that had dealt with these conditions through contemplative practice, ritual grief work, initiatic confrontation with mortality, and other ceremonial techniques had been excluded from legitimate medicine, and the exclusion meant that the alternative to psychiatric pharmacology was not a more effective treatment but rather no treatment at all. The framework’s success in marginalizing its alternatives has been the condition of its subsequent dominance, and the cost of the marginalization has been borne largely by the populations whose conditions the alternatives might have addressed more effectively.
The Pharmakon Capture Risk
The current psychedelic renaissance inherited by Griffiths and the Johns Hopkins program presents the Flexner framework with its most awkward test case. The substances the program is studying — psilocybin, MDMA, ketamine — produce clinical effects that the existing pharmaceutical framework has no adequate account of, through mechanisms that appear to depend on subjective experience in ways that the framework’s methodology was built to exclude from consideration. The Griffiths studies have demonstrated that high-dose psilocybin under therapeutic support produces mystical experiences that subjects rate among the most meaningful events of their lives and that the clinical benefit appears to correlate with the occurrence of these experiences rather than being independent of them. The finding, on the Flexner framework’s own terms, is anomalous: the framework has no way to treat subjective experience as causally operative, no way to incorporate meaning-making into a clinical trial’s dependent variables, and no way to distinguish between a drug that works because of its pharmacology and a drug that works because of what it causes the patient to experience.
The capture risk is that the framework will process the psychedelic renaissance by suppressing the anomalous features until the substances can be fit into the existing template. Psilocybin will be approved as a treatment for treatment-resistant depression on the strength of clinical trial data. The approval will come with a standard pharmaceutical labeling that treats the mystical experience as an incidental side effect rather than the operative mechanism. The administration protocols will be refined toward the kind of session that produces measurable clinical benefit without necessarily producing the experiences the tradition has always understood as central. The pharmaceutical companies that manufacture and distribute the product will capture the profit stream. Insurance reimbursement will be available for FDA-approved indications and will not be available for the broader therapeutic and developmental applications the traditional framework understood the substance to serve. The substance will be legal, available, profitable, and largely disconnected from what the pharmakon tradition had known it to be for three thousand years.
This is not a hypothetical risk. The trajectory is the default behavior of the framework absent specific countervailing pressure, and the institutional infrastructure for this capture is already being assembled. As of 2023–2025, COMPASS Pathways, atai Life Sciences, and several other companies have positioned themselves to commercialize psilocybin therapy within the FDA framework. The intellectual property strategies they have pursued include attempts to patent specific crystalline forms, delivery mechanisms, and administration protocols, securing commercial monopolies over substances whose natural forms have been used ceremonially for millennia. The substances themselves cannot be patented, but the specific commercial forms can be, and the commercial forms are what the framework will recognize as legitimate medicine. The outcome, if the current trajectory continues, is the completion of the Flexner framework’s logic in its application to the psychedelic tradition: the substance becomes a pharmaceutical product, the tradition is excluded as unscientific, and the institutional orthodoxy adds another profitable line to its product catalog without having changed anything fundamental about the framework through which it metabolizes the world.
The Rendering-Model Reading
On the rendering-model reading, Rockefeller Medicine is the twentieth century’s most successful parasitic operation conducted at civilizational scale through institutional rather than overtly coercive means. The operation did not require violence or direct suppression of alternatives in the manner of traditional religious persecution. It required the funding of one tradition and the withholding of funding from its competitors, the credentialing of one framework and the marginalization of others through professional gatekeeping, and the progressive shaping of the cultural environment so that the excluded traditions became unthinkable rather than merely illegal. The operation’s success is measured by the fact that most contemporary Americans cannot imagine a medical framework that is not structured on the Flexner template, and most contemporary Americans do not know that the template was a policy choice made by specific actors in specific historical circumstances for specific commercial reasons. The operation has achieved what successful narrative control always achieves: the erasure of the alternatives from the range of recognized possibilities.
The pattern is the inverted pharmakon: the substances that the traditional framework had regarded as potentially beneficial under ceremonial conditions became patented pharmaceuticals administered under commercial conditions, while the substances that the traditional framework had regarded as sacramental — the psychedelic, the entheogenic, the consciousness-altering — were prohibited entirely for half a century and are now being reintroduced into the framework through the same commercial mechanism that captures everything the framework touches. The original meaning of the word pharmakon — the substance that is both remedy and poison depending on context — has been erased at the level of cultural vocabulary. What remains is the pharmaceutical, which is assumed to be unambiguously remedy, and the drug of abuse, which is assumed to be unambiguously poison, with no recognition that the category itself was always a context-dependent distinction that the traditional framework had understood explicitly and that the modern framework has worked to forget.
The recovery of the pharmakon tradition is the recovery of the ability to distinguish remedy from poison through the attention to context that the traditional framework had always required. This recovery is not compatible with the Flexner framework’s fundamental commitments. The framework treats the substance as causally prior and the context as incidental; the tradition treats the context as partly constitutive and the substance as one element of a relational operation. The two readings cannot be reconciled because they disagree about what medicine fundamentally is. Which reading prevails in the coming generation will determine whether the psychedelic renaissance produces a genuine recovery of the traditional framework or another profitable product line for the orthodoxy it was supposed to challenge.
Open Questions
- Would a counterfactual American medicine that had preserved the pre-Flexner pluralism have produced better health outcomes than the actual outcomes of the twentieth century, and how could such a counterfactual be meaningfully evaluated?
- What specific therapeutic knowledge from the excluded traditions (homeopathy, eclectic medicine, etc.) has been lost that subsequent research might be able to recover?
- Is the Flexner framework capable of internal reform that would accommodate the pharmakon tradition on its own terms, or does the framework’s commitment to the isolated-molecule model make such accommodation structurally impossible?
- What legal and regulatory architecture would be required to permit the traditional framework to operate as a parallel medical tradition with its own licensing, its own practitioners, and its own insurance and reimbursement structures?
- Has the pharmaceutical industry’s demonstrated willingness to misrepresent product safety (opioids, SSRIs in children, hormone replacement therapy, others) reached a threshold at which the framework’s basic credibility should be reconsidered on institutional rather than individual grounds?
References
Angell, Marcia. The Truth About the Drug Companies: How They Deceive Us and What to Do About It. Random House, 2004.
Borkin, Joseph. The Crime and Punishment of IG Farben. Free Press, 1978.
Brown, E. Richard. Rockefeller Medicine Men: Medicine and Capitalism in America. University of California Press, 1979.
Coulter, Harris L. Divided Legacy: A History of the Schism in Medical Thought. Vol. 3: Science and Ethics in American Medicine 1800–1914. North Atlantic Books, 1982.
Flexner, Abraham. Medical Education in the United States and Canada. Carnegie Foundation for the Advancement of Teaching Bulletin No. 4, 1910.
Goldacre, Ben. Bad Pharma: How Drug Companies Mislead Doctors and Harm Patients. Fourth Estate, 2012.
Griggs, Barbara. Green Pharmacy: The History and Evolution of Western Herbal Medicine. Healing Arts Press, 1997.
Haller, John S., Jr. The History of American Homeopathy: The Academic Years, 1820–1935. Pharmaceutical Products Press, 2005.
Healy, David. Pharmageddon. University of California Press, 2012.
Hoxsey, Harry M. You Don’t Have to Die. Milestone Books, 1956.
Keefe, Patrick Radden. Empire of Pain: The Secret History of the Sackler Dynasty. Doubleday, 2021.
Kuttner, Robert. Everything for Sale: The Virtues and Limits of Markets. Knopf, 1997.
Ludmerer, Kenneth M. Time to Heal: American Medical Education from the Turn of the Century to the Era of Managed Care. Oxford University Press, 1999.
Meyers, Morton A. Prize Fight: The Race and the Rivalry to Be the First in Science. Palgrave Macmillan, 2012.
Starr, Paul. The Social Transformation of American Medicine. Basic Books, 1982.
Whitaker, Robert. Mad in America: Bad Science, Bad Medicine, and the Enduring Mistreatment of the Mentally Ill. Perseus Publishing, 2002.
Whitaker, Robert. Anatomy of an Epidemic: Magic Bullets, Psychiatric Drugs, and the Astonishing Rise of Mental Illness in America. Crown, 2010.
Whorton, James C. Nature Cures: The History of Alternative Medicine in America. Oxford University Press, 2002.